Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Evidence: ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial

Generated Narrative: Evidence 47771

version: 10; Last updated: 2023-12-06 17:48:14+0000

Profiles: ComparativeEvidence, SingleStudyEvidence

url: https://fevir.net/resources/Evidence/47771

identifier: FEvIR Object Identifier/47771

name: ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2014_STAMPEDE_trial

title: ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial

status: Active

date: 2022-05-29 11:09:40+0000

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

author: Brian S. Alper:

UseContexts

-CodeValue[x]
*Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication: Evidence CommunicationComparativeEvidence
*Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication: Evidence CommunicationSingleStudyEvidence

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

relatedArtifact

type: Derived From

label: data source

display: Figure 2C

citation:

Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations [Journal Article]. Contributors: Francesco Rubino, David M Nathan, Robert H Eckel, Philip R Schauer, K George M M Alberti, Paul Z Zimmet, Stefano Del Prato, Linong Ji, Shaukat M Sadikot, William H Herman, Stephanie A Amiel, Lee M Kaplan, Gaspar Taroncher-Oldenburg, David E Cummings, Delegates of the 2nd Diabetes Surgery Summit. In: Diabetes care, PMID 27222544. Published June 2016. Available at: https://pubmed.ncbi.nlm.nih.gov/27222544/.

Documents

-Url
*https://diabetesjournals.org/care/article/39/6/861/29305/Metabolic-Surgery-in-the-Treatment-Algorithm-for

relatedArtifact

type: Cite As

citation:

ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial [Evidence]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 47771. Revised 2022-05-29. Available at: https://fevir.net/resources/Evidence/47771. Computable resource at: https://fevir.net/resources/Evidence/47771.

description:

Mean HbA1c at 36 months in Schauer 2014 was 6.85% in Surgery group (n = 97) and 8.4% in Medical/Lifestyle group (n = 40), mean difference -1.55% (95% CI -2.28% to -0.82%)

variableDefinition

description:

137 with uncontrolled T2DM

variableRole: Population

observed: Schauer 2014 (STAMPEDE) Trial Enrollment Group

variableDefinition

description:

Roux-en-Y gastric bypass or Sleeve Gastrectomy vs. medical treatment (intensive medical therapy)

variableRole: Exposure

comparatorCategory: medical treatment

observed: GroupAssignment: Roux-en-Y gastric bypass vs. medical treatment

variableDefinition

description:

HbA1c at 36 months

variableRole: Outcome

observed: OutcomeVariable: HbA1c at 36 months

synthesisType: not applicable

studyDesign: randomized assignment

statistic

description:

mean difference --1.55% (95% CI -2.28% to -0.82%)

note: Mean HbA1c at 36 months in Schauer 2014 was 6.85% in Surgery group (n = 97) and 8.4% in Medical/Lifestyle group (n = 40)

statisticType: Mean Difference

quantity: -1.55 % (Details: UCUM code% = '%')

SampleSizes

-NumberOfParticipantsKnownDataCount
*137137

AttributeEstimates

-DescriptionTypeLevelRange
*

95% CI -2.28% to -0.82%

Confidence interval0.95-2.28--0.82 %